Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2

Eugene J Fine1, Anna Miller, Edward V Quadros

  • 1Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. efine@aecom.yu.edu

Abstract

Insights

Ketone bodies like acetoacetate inhibit aggressive cancer cell growth by reducing ATP production. Overexpression of uncoupling protein 2 (UCP2) in cancer cells, but not normal cells, explains this targeted effect.

Area of Science:

  • Biochemistry
  • Cancer Biology
  • Metabolic Research

Background:

  • Human cancers can uncouple mitochondrial ATP generation despite intact tricarboxylic acid (TCA) enzymes.
  • Uncoupling protein 2 (UCP2) is implicated in cancer's metabolic dysregulation.
  • Ketone bodies are investigated for their potential role in cancer therapy.

Purpose of the Study:

  • To test if ketone bodies inhibit aggressive cancer cell growth.
  • To determine if UCP2 expression contributes to this inhibition.
  • To elucidate the mechanism involving ATP production inhibition.

Main Methods:

  • Seven aggressive human cancer cell lines and three control fibroblast lines were cultured in vitro.
  • Cells were grown in glucose medium or glucose plus acetoacetate medium.
  • Assays measured cell growth, ATP production, and UCP2 expression.

Main Results:

  • Cancer cell growth strongly correlated with ATP concentration (r = 0.948).
  • Cancer lines showed inhibited growth and ATP production, with UCP2 overexpression (p < 0.05).
  • Control fibroblasts exhibited normal growth and ATP levels with low UCP2 staining.

Conclusions:

  • Acetoacetate significantly reduced growth and ATP concentration in seven human cancer cell lines.
  • These effects were not observed in control fibroblasts.
  • UCP2 overexpression in cancer cells, absent in controls, provides a mechanism for acetoacetate's selective suppression of cancer growth, supporting ketogenic diet therapies.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...